We’re delighted to welcome Ternary Therapeutics to the SBC community!

Ternary Tx is a pioneering biotech startup, that announced earlier this month, the launch of its revolutionary AI-driven platform for designing molecular glue therapeutics, opening new frontiers in drug discovery for previously “undruggable” targets.

Their innovative approach has the potential to unlock therapeutic opportunities for up to 85% of disease-causing proteins that have long eluded traditional drug development methods.

Dr Chris Tame, CEO and Founder, said:

“Our platform represents a paradigm shift in how we approach drug discovery for challenging targets.

By harnessing the power of AI and physics-based simulations, we’re able to explore vast chemical spaces and predict protein interactions with unprecedented speed and accuracy.

We’ve chosen to locate our labs in Stevenage at Stevenage Bioscience Catalyst due to proximity to GSK and great links to London. We’re also looking forward to joining the buzzing campus life science community.”

 

The launch of Ternary Tx comes at a time of surging interest in molecular glue degraders, with recent billion-dollar deals highlighting the modality’s potential. Ternary Tx is well-positioned to capitalise on this trend, offering a unique solution to one of the pharmaceutical industry’s most persistent challenges.

We’re excited to have Chris and his team base their lab and office at SBC, and look forward to seeing them grow and scale!

For more information about Ternary Tx and its AI platform, please visit www.ternarytx.co.uk